Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 12/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004036 | 0.83 | GPBAR1 (0.45) | GABRA5GPBAR1FFAR4PTPN1 | |
| SCHEMBL2929499 | 0.81 | CDH1 (0.46) | GPBAR1FFAR4PTPN1LMNA | |
| SCHEMBL25562790 | 0.79 | GPBAR1 (0.42) | GABRA5GPBAR1FFAR4PTPN1CNR1 | |
| SCHEMBL27946184 | 0.79 | SLC6A3 (0.51) | GABRA5GPBAR1PTPN1LMNA | |
| SCHEMBL4762391 | 0.77 | GABRA5 (0.42) | GABRA5GPBAR1FFAR4PTPN1 | |
| SCHEMBL2929533 | 0.75 | SMN1; SMN2 (0.52) | FFAR4LMNA | |
| SCHEMBL22143653 | 0.70 | CYP19A1 (0.54) | GABRA5GPBAR1FFAR4PTPN1LMNA | |
| SCHEMBL10044967 | 0.70 | CHRNA4 (0.43) | — | |
| SCHEMBL2928527 | 0.69 | NOTUM (0.51) | GABRA5FFAR4 | |
| SCHEMBL5772712 | 0.69 | FFAR4 (0.66) | GABRA5FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4177249-A1 | IMMUNOMODULATOR | Hitgen Inc. (CN) | 2023-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | GABRA5 657/4885GPBAR1 156/4885FFAR4 1984/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | GABRA5 521/4885GPBAR1 210/4885FFAR4 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.